David Robbins, MD was asked by Procept BioRobotics to be the first urologist in South Florida to be trained on and be able to offer Aquablation therapy to patients with enlarged prostate (BPH).
PROCEPT BiopRobotics developed the AquaBeam System that delivers Aquablation therapy, a revolutionary new surgical option for the treatment of benign prostatic hyperplasia (BPH). The AquaBeam System is the first FDA approved robotic surgical system capable of providing autonomous removal of prostate tissue for the treatment of symptomatic BPH or enlarged prostate.
Aquablation therapy is a procedure that combines the clarity of real time multi-dimensional ultrasound imaging with the precision of an autonomous state of the art surgical robot and heat-free water jet ablation for targeted, controlled and immediate removal of BPH prostate tissue to optimize surgical outcomes for enlarged prostate and resolve lower urinary tract symptoms (LUTS). Aquablation is the only procedure for BPH to combine the proven efficacy of transurethral resection of the prostate (TURP), the current gold standard or BPH surgery, with the decreased risk of sexual side effects promoted in non tissue removing procedures such as Rezum and Urolift.
Integration of real time cystoscopic imaging with intra-operative ultrasound provides the surgeon with improved decision making and presonalized treatment planning for each patient.
The Aquabeam robotic surgical system executes the treatment plan set up by the surgeon, guiding the precisely alligned heat-free waterjet rapidly and accurately providing reproducible and consistent results.
Harnesssing the intense power of water pulsating at near the speed of sound, Aquablation accurates removes BPH tissue using a heat-free waterjet thereby eliminating thermal injury complications during the procedure.